motesanib + panitumumab + FOLFIRI

This is an investigational **combination therapy** consisting of motesanib (a small molecule angiogenesis inhibitor), panitumumab (a fully human anti-EGFR monoclonal antibody), and FOLFIRI (a standard chemotherapy regimen containing folinic acid [leucovorin], fluorouracil [5-FU], and irinotecan). - **Motesanib** is a small molecule inhibitor of VEGF receptors, PDGFR, and Kit, blocking angiogenesis required for tumor growth. - **Panitumumab** is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting EGFR-mediated cell growth signaling primarily in KRAS wild-type colorectal cancer. - **FOLFIRI** is a cytotoxic chemotherapy regimen: irinotecan inhibits topoisomerase I; 5-FU is a pyrimidine antagonist, inhibiting DNA synthesis and causing cell death; folinic acid enhances 5-FU efficacy[1][2][3]. This combination has been investigated primarily for metastatic colorectal cancer, especially in KRAS wild-type populations, in clinical trials and not as a standard-of-care regimen.

Other names

motesanibAMG 706AMG706AMG-706panitumumabABX-EGFVectibixFOLFIRIfolinic acid + fluorouracil + irinotecan